Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Activity of SYK and PLCγ2 Predict Apoptotic Response of Chronic Lymphocytic Leukemia Cells to SRC Tyrosine Kinase Inhibitor Dasatinib.

Y. Lynn Wang, MD, PhD, Zibo Song, Pin Lu, Richard R Furman, John P. Leonard, MD, Peter Martin, Lauren Tyrell, Francis Y. Lee, Daniel M. Knowles, Morton Coleman

Blood (2009) 114 (22): 1249.

https://doi.org/10.1182/blood.V114.22.1249.1249

Published: 2009

Journal Articles

Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation.

Gary L Schieven, Rosemary Zhang, Sidney Pitt, Kelly McGlinchey, Krista Menard, Richard Smykla, Vojkan Susulic, Mei-Li Wen, Amy Wiebesiek, Robert Townsend, Francis Y. Lee

Blood (2009) 114 (22): 2198.

https://doi.org/10.1182/blood.V114.22.2198.2198

Published: 2009

Journal Articles

Targeting Early Events of B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia: Suppressed Syk and PLCγ2 Activities Predict Apoptotic Response of Leukemic Cells to Dasatinib

Y. Lynn Wang, MD, PhD, Zibo Song, Pin Lu, John P. Leonard, Morton Coleman, Peter Martin, Chaowei Wu, Francis Y. Lee, Daniel M. Knowles, Richard Furman

Blood (2008) 112 (11): 5023.

https://doi.org/10.1182/blood.V112.11.5023.5023

Published: 2008

Journal Articles

The effects of dasatinib on IgE receptor–dependent activation and histamine release in human basophils

Michael Kneidinger, Uwe Schmidt, Uwe Rix, Karoline V. Gleixner, Anja Vales, Christian Baumgartner, Christian Lupinek, Margit Weghofer, Keiryn L. Bennett, Harald Herrmann, Alexandra Schebesta, Wayne R. Thomas, Susanne Vrtala, Rudolf Valenta, Francis Y. Lee, Wilfried Ellmeier, Giulio Superti-Furga, Peter Valent

Blood (2008) 111 (6): 3097–3107.

https://doi.org/10.1182/blood-2007-08-104372

Published: 2008

Journal Articles

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

Mhairi Copland, Francesca Pellicano, Linda Richmond, Elaine K. Allan, Ashley Hamilton, Francis Y. Lee, Roberto Weinmann, Tessa L. Holyoake

Blood (2008) 111 (5): 2843–2853.

https://doi.org/10.1182/blood-2007-09-112573

Published: 2008

Includes: Supplemental data

Journal Articles

In Vitro Cardiotoxicity Potential Comparative Assessments of Chronic Myelogenous Leukemia Tyrosine Kinase Inhibitor Therapies: Dasatinib, Imatinib and Nilotinib.

Wendy J. Freebern, PhD, Hengsheng S. Fang, Martin D. Slade, Susan Wells, Jennifer Canale, John Megill, Branka Grubor, PhD, DVM, Hong Shi, Anthony Fletcher, DVM, Louis Lombardo, Paul Levesque, Francis Y. Lee, Vito G. Sasseville, PhD, DVM

Blood (2007) 110 (11): 4582.

https://doi.org/10.1182/blood.V110.11.4582.4582

Published: 2007

Journal Articles

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karoline Sonneck, MD, Alexander Gruze, Puchit Samorapoompichit, MD, Karl J. Aichberger, MD, Francis Y. Lee, PhD, Paul W. Manley, PhD, Doriano Fabbro, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 526.

https://doi.org/10.1182/blood.V108.11.526.526

Published: 2006

Journal Articles

Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.

Michael Kneidinger, MD, Peter Valent, MD, Karoline V. Gleixner, MD, Stefan Florian, MD, Alexandra Boehm, MD, Karoline Sonneck, MD, Margit Weghofer, Christian Lupinek, Susanne Vrtala, MD, Anja Vales, MD, Rudolf Valenta, MD, Giulio Superti-Furga, PhD, Francis Y. Lee, PhD

Blood (2006) 108 (11): 1365.

https://doi.org/10.1182/blood.V108.11.1365.1365

Published: 2006

Journal Articles

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N -ethyl- N -nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations

Heather A. Bradeen, Christopher A. Eide, Thomas O'Hare, Kara J. Johnson, Stephanie G. Willis, Francis Y. Lee, Brian J. Druker, Michael W. Deininger

Blood (2006) 108 (7): 2332–2338.

https://doi.org/10.1182/blood-2006-02-004580

Published: 2006

Includes: Supplemental data

Journal Articles

Dasatinib (BMS-354825) inhibits KIT D816V , an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

Neil P. Shah, Francis Y. Lee, Roger Luo, Yibin Jiang, Marjolein Donker, Cem Akin

Blood (2006) 108 (1): 286–291.

https://doi.org/10.1182/blood-2005-10-3969

Published: 2006

Journal Articles

Targeting BCR-ABL Kinase Activity-Independent Signaling Pathways and Leukemia Stem Cells Is Essential for Curative Therapy of Philadelphia Chromosome Positive (Ph+) Leukemia.

Shaoguang Li, MD, PhD, Yiguo Hu, MD, Sarah Swerdlow, BS, Theodore M. Duffy, MS, Roberto Weinmann, PhD, Francis Y. Lee, PhD

Blood (2005) 106 (11): 1990.

https://doi.org/10.1182/blood.V106.11.1990.1990

Published: 2005

Journal Articles

Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.

Francis Y. Lee, PhD, Mei-Li Wen, M.Sc., Amy Camuso, B.Sc, Stephen Castenada, B.Sc, Krista Fager, M.Sc., Christine Flefleh, B.Sc, Ivan Inigo, B.Sc, Roger Luo, PhD, David Kan, B.Sc, Veeraswamy Manne, PhD, Kelly McGlinchey, B.Sc, Richard Smykla, B.Sc, Roberto Weinmann, PhD, Robert Kramer, PhD

Blood (2005) 106 (11): 1993.

https://doi.org/10.1182/blood.V106.11.1993.1993

Published: 2005

Journal Articles

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

Francis Y. Lee, PhD, Mei-Li Wen, M.Sc., Rajeev Bhide, PhD, Amy Camuso, B.Sc, Stephen Castenada, B.Sc, Krista Fager, B.Sc, Christine Flefleh, B.Sc, Ivan Inigo, B.Sc, David Kan, B.Sc, Roger Luo, PhD, Kelly McGlinchey, B.Sc, Richard Smykla, B.Sc, Robert Wild, PhD, Robert Borzilleri, PhD, Louis Lombardo, PhD

Blood (2005) 106 (11): 1994.

https://doi.org/10.1182/blood.V106.11.1994.1994

Published: 2005

Journal Articles

Targeting Chronic Myeloid Leukemia (CML) Stem Cells by BMS-214662 in Mice.

Cong Peng, MS, Yiguo Hu, MD, Francis Y. Lee, PhD, Shaoguang Li, MD, PhD

Blood (2005) 106 (11): 2861.

https://doi.org/10.1182/blood.V106.11.2861.2861

Published: 2005

Journal Articles

Dasatinib (BMS-354825), a Multi-Targeted Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane and Activation Loop Mutant Kit Isoforms Associated with Human Malignancies.

Marcus M. Schittenhelm, MD, Sharon Shiraga, Arin Schroeder, Amie S. Corbin, Diana Griffith, Francis Y. Lee, PhD, Michael W. Deininger, MD, PhD, Brian J. Druker, MD, Michael C. Heinrich, MD

Blood (2005) 106 (11): 3358.

https://doi.org/10.1182/blood.V106.11.3358.3358

Published: 2005

Journal Articles

Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma.

Qingwei Deng, Nicholas Mitsiades, Joseph Negri, Zhaoqin Wen, Melissa Rooney, Teru Hideshima, Dharminder Chauhan, Nikhil C. Munshi, Paul G. Richardson, Francis Y. Lee, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2005) 106 (11): 1571.

https://doi.org/10.1182/blood.V106.11.1571.1571

Published: 2005

Journal Articles

Simultaneous Targeting of SRC and BCR-ABL Kinases by BMS-354825 Cures Ph+ Acute Lymphoblastic Leukemia in Mice.

Shaoguang Li, MD, PhD, Yiguo Hu, BS, Sarah J. Swerdlow, BS, Francis Y. Lee, PhD

Blood (2004) 104 (11): 1976.

https://doi.org/10.1182/blood.V104.11.1976.1976

Published: 2004

Journal Articles

Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.

Feng Roger Luo, Ph.D., Zheng Yang, Ph.D., Amy Camuso, B.S., Richard Smykla, B.S., Stephen Castenada, B.S., Christine Flefleh, B.S., Krista Fager, M.S., Ivan Inigo, B.S., David Kan, B.S., Kelly McGlinchey, B.S., Mei-Li Wen, M.S., Robert Wild, Ph.D., Robert Borzilleri, Ph.D., Louis Lombardo, Ph.D., Robert Kramer, Ph.D., Francis Y. Lee, Ph.D.

Blood (2004) 104 (11): 1987.

https://doi.org/10.1182/blood.V104.11.1987.1987

Published: 2004

Journal Articles

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.

Robert Wild, Ph.D., Stephen Castaneda, B.S., Christine Flefleh, B.S., Krista Fager, B.S., Ivan Inigo, B.S., David Kan, B.S., Richard Smykla, B.S., Amy Camuso, B.S., Kelly McGlinchey, B.S., Mei-Li Wen, B.S., Feng Roger Luo, Ph.D., Robert Borzilleri, Ph.D., Louis Lombardo, Ph.D., Robert Kramer, Ph.D., Francis Y. Lee, Ph.D.

Blood (2004) 104 (11): 1988.

https://doi.org/10.1182/blood.V104.11.1988.1988

Published: 2004

Journal Articles

BMS-354825 Potently Inhibits the Kinase Activity of KIT Activation Loop Mutations Associated with Systemic Mastocytosis and Induces Apoptosis of Mastocytosis Cell Lines.

Marcus Schittenhelm, M.D., Sharon Shiraga, Francis Y. Lee, Ph.D., Michael C. Heinrich, M.D.

Blood (2004) 104 (11): 2424.

https://doi.org/10.1182/blood.V104.11.2424.2424

Published: 2004

NARROW

Activity of SYK and PLCγ2 Predict Apoptotic Response of Chronic Lymphocytic Leukemia Cells to SRC Tyrosine Kinase Inhibitor Dasatinib.

Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation.

Targeting Early Events of B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia: Suppressed Syk and PLCγ2 Activities Predict Apoptotic Response of Leukemic Cells to Dasatinib

The effects of dasatinib on IgE receptor–dependent activation and histamine release in human basophils

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

In Vitro Cardiotoxicity Potential Comparative Assessments of Chronic Myelogenous Leukemia Tyrosine Kinase Inhibitor Therapies: Dasatinib, Imatinib and Nilotinib.

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N -ethyl- N -nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations

Dasatinib (BMS-354825) inhibits KIT D816V , an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

Targeting BCR-ABL Kinase Activity-Independent Signaling Pathways and Leukemia Stem Cells Is Essential for Curative Therapy of Philadelphia Chromosome Positive (Ph+) Leukemia.

Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

Targeting Chronic Myeloid Leukemia (CML) Stem Cells by BMS-214662 in Mice.

Dasatinib (BMS-354825), a Multi-Targeted Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane and Activation Loop Mutant Kit Isoforms Associated with Human Malignancies.

Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma.

Simultaneous Targeting of SRC and BCR-ABL Kinases by BMS-354825 Cures Ph+ Acute Lymphoblastic Leukemia in Mice.

Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.

BMS-354825 Potently Inhibits the Kinase Activity of KIT Activation Loop Mutations Associated with Systemic Mastocytosis and Induces Apoptosis of Mastocytosis Cell Lines.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only